# Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

> **NCT03423446** · PHASE1 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Telotristat Ethyl

## Key facts

- **NCT ID:** NCT03423446
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2018-06-15
- **Final completion:** 2018-06-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03423446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03423446, "Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03423446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*